Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer

15 Oct 2019

Abstract excerpt

Abstract A priority in cancer research is to innovate therapies that are not only effective against tumor progression but also address comorbidities such as cachexia that limit quality and quantity of life. We demonstrate that TLR7/8 agonist R848 induces anti-tumor responses and attenuates cachexia in murine models of pancreatic ductal adenocarcinoma (PDAC). In vivo, tumors from two of three cell lines were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immune Response and Inflammation
Share to Lung Cancer Research Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31615993
DOI: 10.1038/s41467-019-12657-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancerPMID 31615993Read ↗

The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune SuppressionSemantic proximity Read ↗

High-fat diet imprints a macrophage-tumor CAMP-P2RX7 axis driving pancreatic cancer initiation, plasticity and metastasisSemantic proximity Read ↗

An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer.Semantic proximity Read ↗

T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Inhibition of SUMOylation Induces Adaptive Antitumor Immunity against Pancreatic Cancer through Multiple Effects on the Tumor MicroenvironmentSemantic proximity Read ↗

Advancing Immunotherapy in Pancreatic Cancer: A Brief Review of Emerging Adoptive Cell TherapiesSemantic proximity Read ↗

Precision Medicine: IL-1RA and Pancreatic Cancer OrganoidsSemantic proximity Read ↗

Tissue-resident natural killer cells support survival in pancreatic cancer through promotion of cDC1-CD8 T activitySemantic proximity Read ↗

New horizons in cancer immunotherapy: The evolving role of R848 and R837 (Review)Semantic proximity Read ↗

Driving tumor-associated macrophages to a CXCL9Hi/SPP1Low phenotype eliminates pancreatic cancer.Semantic proximity Read ↗

Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer.Semantic proximity Read ↗

Context-specific GITR agonism potentiates anti-PD-L1 and CD40-based immuno-chemotherapy combination in heterogeneous pancreatic tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.